Find latest Neuroendocrine Tumor videos
·
100+ videos
Video Player is loading.
10 seconds
Playback speed
Overview of NETs: Key Trials and Takeaways
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
Comments 0
Login to view comments.
Click here to Login
